The sequential revenue growth and Nasdaq compliance restoration are positive, but the net profit is entirely from a non-cash debt extinguishment gain and cash is burning quickly ($0.48M vs $2.46M last quarter). Watch for the conversion of the HMO MOU into a definitive agreement and whether Corexa Pharmacy's revenue growth can sustain without further dilution or debt restructuring.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 16 $0.6421entry
- T+1 · 11h ago −0.28%α +0.73% · $0.6403
- T+5 · in 6d Pending
- T+20 · in 28d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
DataMEDS AI reported Q3 2026 revenue of $2.67 million, up 50% sequentially from Q2 2026's $1.78 million, and generated GAAP net income of $10.5 million ($2.72 diluted EPS) versus a $34.3 million loss a year ago, driven by a $19.1 million gain on debt extinguishment. The company also regained full Nasdaq compliance, launched the Health Lives Here app with NFL Alumni Health, and signed an MOU with a Florida HMO covering 25,000+ members. However, revenue declined 11.4% YoY from $3.01 million, and the net profit was entirely from non-operating debt gains, with a $3.4 million operating loss.
Key Financial Metrics
Key Facts
- Q3 2026 revenue of $2,668,980, up 50% sequentially from Q2 2026's $1,779,860 but down 11.4% from $3,012,904 in Q3 2025
- GAAP net income of $10,535,560 ($2.72 diluted EPS) vs net loss of $34,318,204 ($23.07 loss per share) in Q3 2025
- Net income driven by $19,064,881 gain on extinguishment of debt; operating loss was $3,373,956
- Cash and cash equivalents fell to $476,598 from $2,456,373 at June 30, 2026
- Regained full compliance with Nasdaq listing standards on October 19, 2026
- Launched Health Lives Here mobile app with NFL Alumni Health marketing platform
- Signed non-binding MOU with Florida HMO to deploy app to 25,000+ members
- Acquired Helomics cancer diagnostics laboratory in September 2026
- Obtained exclusive license to REBOOT GLP-1 patient management platform in October 2026
- Corexa Pharmacy launched compounded peptides under FDA Enforcement Discretion Policy in November 2026
Financial Impact
Revenue $2.67M (Q3 2026), GAAP net income $10.5M, operating loss $3.4M, cash $0.48M
Risk Factors
- Cash balance of $476,598 is very low relative to current liabilities of $37.9M, raising going-concern risk
- Revenue declined 11.4% YoY; the sequential growth is from a low base and may not be sustainable
- Net profit is entirely from a non-operating $19.1M debt extinguishment gain; operating loss of $3.4M persists
- Convertible notes payable increased to $15.3M from zero at year-end 2025, adding dilution risk
- HMO MOU is non-binding and may not result in a definitive agreement
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-051734 |
| Document: form8-k.htm | 0001493152-26-051734 |
| Document: 0001493152-26-051734-index-headers.html | 0001493152-26-051734 |
| Document: 0001493152-26-051734-index.html | 0001493152-26-051734 |
| Document: 0001493152-26-051734.txt | 0001493152-26-051734 |
| 8-K Data (Synthetic) | 0001493152-26-051734 |
Track record
15 reports on MEDS
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +35.05% at T+60 after the Aug 18, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 17, 2026today 424B5 Bearish 6/10 Entry price pending
- Nov 17, 2026today 8-K Bearish 7/10 Entry $0.6151 Now $0.6403 −4.10% settles Nov 25
- Nov 16, 20261d ago 424B5 Bearish 5/10 Entry $0.6421 Now $0.6403 +0.28% settles Nov 23
- Nov 16, 20261d ago 8-K Neutral 3/10 Entry $0.6421 Now $0.6403 −0.28% settles Nov 23
- Nov 13, 20264d ago 8-K Neutral 5/10 Viewing Entry $0.6421 Now $0.6403 −0.28% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 4/10 Entry $0.9531 Now $0.6403 −32.82% settles Nov 18
- Nov 10, 20267d ago S-1/A Bearish 6/10 Entry $0.9531 Now $0.6403 +32.82% settles Nov 18
- Nov 5, 202612d ago 8-K Neutral 4/10 Entry $1.22 to $0.8702 Now $0.6403 −47.52% ▼ −28.67% −31.96% vs SPY
- Oct 26, 202622d ago 8-K Bearish 6/10 Entry $2.06 to $1.80 Now $0.6403 +68.92% ▲ +12.62% +10.63% vs SPY
- Oct 20, 202628d ago 8-K Neutral 4/10 Entry $2.75 to $2.06 Now $0.6403 −76.72% ▼ −25.09% −25.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers